Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
11actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-05-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-26 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: ABBV-932
Primary outcomes
what the primary-completion date above is the date OFChange in Dopamine Receptor Occupancy in Brain Measured by Positron Emission Tomography (PET)
measured Up to approximately 14 days
Number of Participants with Adverse Events (AEs)
measured Up to approximately 74 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed